Trulieve Cannabis is growing its four-day winning streak by closing at $6.56, gaining 0.96%.

A quick look at yesterday: after closing at $6.5 on Friday, Trulieve Cannabis maintained a strong bullish bias that helped the stock close higher at $6.56 yesterday. However, market bears ensured the the medical and recreational cannabis provider topped out at $6.65 and that by the end of the session, the market had marked out a distinct $6.37 to $6.65 range.

United States Fed Chair Powell testimony is next today at 15:00 UTC.

Meanwhile, United States Factory Orders beat the -1.8% projections, with -1.6%.

Trulieve Cannabis Corp. made an initial breakout above its 21 day Simple Moving Average at $6.45, a potential indicator of a newly emerging bullish phase. Despite this, Trulieve Cannabis could be slowing down soon; it is getting close to the resistance line and is now at $6.68, only 12 cents away. Crossing the resistance line could, however, suggest that further gains are ahead.

Overall, looking at the technical analysis landscape, it seems Trulieve Cannabis might continue pointing upwards in the short term.

This rally in Trulieve Cannabis's share price coincided with other health care stocks as Merck gained 3.95%, as it traded at $111.1.

While Trulieve Cannabis was bullish yesterday, the following health care stocks underperformed: Medtronic went down to $81.93, losing 1.77% after it closed at $83.41 yesterday. Abbott Laboratories went down 1.63%, closed at $104.45.

Furthermore, the market is looking at tomorrow at 15:30 UTC data for United States Crude Oil Inventories will be released, with an expected decline to -308,000 from the preceding figure of 1.17 million.

Furthermore, the market is looking at United States ADP Nonfarm Employment Change (Feb) is expected tomorrow at 13:15 UTC. United States JOLTs Job Openings (Jan) scheduled to come out tomorrow at 15:00 UTC.

The medical and recreational cannabis provider has shed 51.98% over the past three months.